हिंदी में पढ़ें

Dr Reddy's Laboratories

Dr Reddy's Labs gets Rs 27 lakh penalty from Mexican drug regulator

Dr Reddy's Labs gets Rs 27 lakh penalty from Mexican drug regulator

Thu, Nov 14, 2024

The fine was imposed due to an error in the date of the invoice and also in the name of the reference standard versus import license.

Dr Reddy's fined Rs 28 lakh by Mexican drug regulator

Dr Reddy's fined Rs 28 lakh by Mexican drug regulator

Thu, Sep 26, 2024

The drug regulatory body of Mexico has imposed a penalty of MXN 6,51,420 (Rs 28 Lakh) on the company for deviation from prescribed guidelines for filing intimation of import of a reference standard for one of the active pharmaceutical ingredient

Dr Reddy's Laboratories share price: Company gets establishment inspection report from USFDA for Visakhapatnam units

Dr Reddy's Laboratories share price: Company gets establishment inspection report from USFDA for Visakhapatnam units

Mon, Aug 12, 2024

Earlier, the USFDA had issued a Form 483 with two observations to the two units following inspection which was conducted from May 8 to May 17, 2024.

TRENDING NOW

Stock of the Day: What is Anil Singhvi's opinion on Dr Reddy's Laboratories?

Stock of the Day: What is Anil Singhvi's opinion on Dr Reddy's Laboratories?

Thu, Jun 27, 2024

Stock of the Day: What is Anil Singhvi's opinion on Dr Reddy's Laboratories? See in this video.

Dr Reddy's Labs Q4 results miss estimates, stock slips nearly 5%; Should you buy, sell or hold?

Dr Reddy's Labs Q4 results miss estimates, stock slips nearly 5%; Should you buy, sell or hold?

Wed, May 08, 2024

Dr Reddy's Labs share price: Dr Reddy's Laboratories reported a 36 per cent increase in its consolidated profit after tax at Rs 1,307 crore for the quarter that ended March 2024, aided by robust sales in the US market.

Dr Reddy's Labs enters into distribution partnership with Sanofi India; stock rises

Dr Reddy's Labs enters into distribution partnership with Sanofi India; stock rises

Thu, Mar 28, 2024

As of 11:04 a.m., shares of Dr Reddy's Laboratories traded 1.65 per cent or Rs 99.5 higher, at Rs 6,147.1 apiece on BSE. The market capitalisation of the company at around the same time stood at Rs 1,02,379.92 crore.

Breaking News | Complaint in US court against Dr Reddy's subsidiary

Breaking News | Complaint in US court against Dr Reddy's subsidiary

Fri, Mar 01, 2024

BreakingNews | Complaint in US court against Dr Reddy's subsidiary, complaint in case related to generic Revlimid drug Allegation of monopoly of generic Revlimid drug.

Dr Reddy's Labs hits an all-time high after US FDA issues EIR to its Hyderabad facility

Dr Reddy's Labs hits an all-time high after US FDA issues EIR to its Hyderabad facility

Mon, Feb 12, 2024

After closing at Rs 6152.45 on Friday evening, the stock of Dr. Reddy's Laboratories started its journey on Monday at Rs 6200.05. It jumped to its all-time high minutes after starting the trading session on Monday.

Dr Reddy's Laboratories zooms to an all-time time after reporting above-estimate December quarter results

Dr Reddy's Laboratories zooms to an all-time time after reporting above-estimate December quarter results

Wed, Jan 31, 2024

The company's consolidated profit after tax (PAT) jumped by 11 per cent, while its revenue from operations was up by seven per cent Year-on-Year (YoY).

Dr Reddy's Labs Hyderabad facility gets 9 observations from US drug regulator; shares fall

Dr Reddy's Labs Hyderabad facility gets 9 observations from US drug regulator; shares fall

Fri, Oct 13, 2023

At around 12:42 p.m., shares of Dr Reddy's Laboratories traded 0.85 per cent or Rs 46.8 lower at Rs 5,483.1 apiece. The stock fell for the second straight day and the market capitalisation of the company stood at Rs 91,737.16 crore.

Dr Reddy's Q4 2023 preview: Here is what to expect from the drug maker

Dr Reddy's Q4 2023 preview: Here is what to expect from the drug maker

Tue, May 09, 2023

Dr Reddy Q4 results 2023 preview: The pharmaceutical company is likely to report a 13 per cent year-on-year (YoY) increase in its consolidated revenue to Rs 6,174 crore against Rs 5,475 crore logged in Q4FY2023, according to Zee Business Research.

Top Gainers & Losers: Dr Reddy’s Labs, Bajaj Auto end in green, Power Grid dips nearly 2%

Top Gainers & Losers: Dr Reddy’s Labs, Bajaj Auto end in green, Power Grid dips nearly 2%

Wed, Apr 12, 2023

Top Gainers & Losers: TCS will kick start the Q4 earnings season later in the day. Industrial Production data for February and March inflation rates are scheduled to be announced post-market hours.

Pharma stocks a mixed bag as drug regulator NPPA fixes retail price of 74 drug formulations

Pharma stocks a mixed bag as drug regulator NPPA fixes retail price of 74 drug formulations

Tue, Feb 28, 2023

The National Pharmaceutical Pricing Authority (NPPA) on Monday fixed the prices under the Drugs (Price Control) Order 2013 based on the decision of the 109th authority meeting held on February 21 this year, according to a PTI report.

Wipro, Bajaj Auto, Dr Reddy's among stocks in focus today | Check What Brokerage firm Recommends

Wipro, Bajaj Auto, Dr Reddy's among stocks in focus today | Check What Brokerage firm Recommends

Tue, Feb 28, 2023

Brokerages are bullish on Dr Reddy's Laboratories, Bajaj Auto, and skeptical on Wipro. Here's what top brokerages recommend on some of the key stocks in focus today.

Dr Reddy's to buy US generic product portfolio of Australia-based Mayne Pharma

Dr Reddy's to buy US generic product portfolio of Australia-based Mayne Pharma

Mon, Feb 27, 2023

The acquisition will complement Dr Reddy's US retail prescription pharmaceutical business with limited competition products.

Tata Motors, Bajaj Auto, Dr Reddy’s Laboratories, and Cipla are in focus ahead of Q3 results today

Tata Motors, Bajaj Auto, Dr Reddy’s Laboratories, and Cipla are in focus ahead of Q3 results today

Wed, Jan 25, 2023

Shares of Tata Motors and Bajaj Auto were trading flat with a positive bias at Rs 422.40 and Rs 3,693 per share on the NSE in the early morning session on Wednesday.

Dr Reddy's Lab completes Phase 1 study of proposed arthritis drug

Dr Reddy's Lab completes Phase 1 study of proposed arthritis drug

Mon, Dec 19, 2022

The company further said it is initiating a global Phase III study to compare the efficacy, safety, tolerability and immunogenicity of 'DRL_TC' with the reference product in patients with moderate-to-severe active rheumatoid arthritis.

Dr Reddy’s out of Sensex pack; Tata Motors is new entrant - Check full list of 30 companies | Sensex Reshuffle December 2022

Dr Reddy’s out of Sensex pack; Tata Motors is new entrant - Check full list of 30 companies | Sensex Reshuffle December 2022

Mon, Dec 19, 2022

Dr Reddy’s Lab Share Price: Zee Business panellist and market expert Jay Thakkar said that Dr Reddy’s shares are trading in a range from Rs 4650 to Rs 3750. He, however, said that the range is contracting gradually and trading between Rs 4250 and Rs 4650.

Sensex Companies List 2022: Tata Motors to replace Dr Reddy's in S&P BSE Sensex from tomorrow

Sensex Companies List 2022: Tata Motors to replace Dr Reddy's in S&P BSE Sensex from tomorrow

Fri, Dec 16, 2022

Sensex reshuffle: The rejig in the benchmark index is a part of the periodic reshuffle done in the index. The reshuffle happens twice a year -- June and December. It is based on a float-adjusted market cap weighted methodology.

Dr Reddy's, Sun Pharma recall products in US for manufacturing issues

Dr Reddy's, Sun Pharma recall products in US for manufacturing issues

Mon, Dec 05, 2022

As per the enforcement report by the US health regulator, the US-based arm of Dr Reddy's Laboratories is recalling over 48,000 cartons of a drug used to treat sneezing, runny or stuffy nose.

Sensex reshuffle: Tata Motors to replace Dr Reddy’s, effective from December 19

Sensex reshuffle: Tata Motors to replace Dr Reddy’s, effective from December 19

Mon, Nov 21, 2022

Sensex reshuffle: Indian automotive manufacturer Tata Motors will replace pharmaceutical company Dr Reddy’s Laboratories in the 30-share benchmark S&P BSE Sensex effective Monday, December 19, 2022.

Dr Reddy's Laboratories share trade in green in early trade with over 1% surge after Q2 result: Check target given by brokerages

Dr Reddy's Laboratories share trade in green in early trade with over 1% surge after Q2 result: Check target given by brokerages

Mon, Oct 31, 2022

Dr Reddy share price: Dr Reddy's stock was trading in green on both the indices with more than 1 per cent surge.

Dr Reddy's Lab inks licensing pact with US-based Slayback Pharma

Dr Reddy's Lab inks licensing pact with US-based Slayback Pharma

Sat, Jul 30, 2022

The company has inked a licensing pact with the NewJersey-based drug firm to acquire rights in Brimonidine Tartrate Ophthalmic Solution 0.025 percent, the Hyderabad-based firm said in a statement.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x